NasdaqGS:COGTBiotechs
Assessing Cogent Biosciences (COGT) Valuation After FDA Breakthrough Therapy And Real Time Oncology Review News
Cogent Biosciences (COGT) recently reported two closely linked FDA milestones for its lead cancer therapy, and those regulatory updates are now central to how many investors are thinking about the stock.
See our latest analysis for Cogent Biosciences.
The FDA’s Breakthrough Therapy Designation and Real-Time Oncology Review decision arrived after a period of very strong market interest, with the share price at $37.28 and a 90 day share price return of 158.53%. The 1 year total shareholder...